Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of TAS3351 in EGFR-mutated Advanced NSCLC
jRCT2031220742Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of TAS3351 in EGFR-mutated non-small cell lung cancer, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS3351 and Objective response rate (ORR) per RECIST v1.1. Started Apr 2023; status: completed.
02
Drugs
TAS3351
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2031220742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220742.